Therapy of Acromegaly with SMS 201-995: Long-Term Studies

Tolis, G.; Malachtari, S.; Mortoglou, A; Rigas, George; Saridakis, C.; Kamillaris, T.; Andreou, John; Kimpouris, Y.; Pozo, E. del; Yotis, A

doi:10.3109/00365528609087443

Cited by 6 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment of acromegaly with SMS 20 1-995 has not induced significant changes in fasting blood glucose level and the mean glucose concentration in the 24-h glucose profile Barnard et al, 1986;Tolis, 1988;Barkan et al, 1988; Pg Per day * et al, 1986). Verschoor et al (1986) reported that plasma insulin levels were suppressed 2-2.5 h after each injection of SMS 201-995 in patients who had long-term (1year) treatment.…”

Section: Discuss1 Onmentioning

confidence: 99%

“…Previous studies showed that SMS 201 -995 is efficacious not only for newly diagnosed patients but also for patients who had not responded to previous surgical andfor radiotherapeutic treatment (Ch'ng et al, 1985;Lamberts et al, 1985;Tolis et al, 1986a, b;Plewe et af., 1984;Wass et al, 1986;Barnard et af., 1986;Tolis, 1988;Plockinger & Quabbe, 1988;Barkan et al, 1988). However, some patients in the above studies were still insensitive or resistant to SMS 201-995.…”

Section: Discuss1 Onmentioning

confidence: 99%

“…The range of the effective dosage of SMS 201-995 reported in literature varies from 75 to 1500 pg daily (Ch'ng et al, 1985;Lamberts er al., 1985;Tolis et al, 1986a, b;Plewe et al, 1984;Wass et al, 1986;Barnard et al, 1986;Tolis, 1988;Plockinger & Quabbe, 1988;Barkan et al, 1988). Barnard et al (1986) showed that serum GH levels could be suppressed when the immunoreactive blood levels of SMS 20 1-995 were above 70 pg/ml.…”

Section: Discuss1 Onmentioning

confidence: 99%

See 2 more Smart Citations

Clinical and Biochemical Effects of Incremental Doses of the Long‐acting Somatostatin Analogue SMS 201‐995 in Ten Acromegalic Patients

Shi

Harris

Zhu

et al. 1990

Clinical Endocrinology

View full text Add to dashboard Cite

Ten patients (seven women, three men) with active acromegaly, five previously treated and five newly diagnosed, were included in an open-label prospective trial of 3 daily subcutaneous injections of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) at increasing doses in order to obtain maximum growth hormone (GH) suppression. Four patients had received surgery, radiotherapy or bromocriptine. SMS 201-995 doses were increased in a stepwise fashion from 100 micrograms every 8 h (three times daily) to 200, 300 and finally 500 micrograms three times daily at monthly intervals if mean serum GH values failed to decrease to undetectable levels in over 75% of the samples. The optimal dose was maintained for up to 28 months. Significant clinical improvement of headache, soft tissue swelling, facial features, hyperhidrosis and paraesthesia occurred in all patients. Mean 12-h GH levels were significantly suppressed in four patients and fell to normal values in four. Suppression of GH levels was not achieved in two patients. Comparison of the mean interindividual GH values shows that the optimal efficacious dose is 100 micrograms t.i.d. in 7/10 patients. Somatomedin-C (SM-C) was also significantly reduced to below 50% of pretreatment levels in nine patients in whom it was measured. The subsequent increments of SMS 201-995 up to 500 micrograms three times daily did not produce further clinically relevant GH or SM-C suppression. Pituitary tumour shrinkage occurred in five patients. Thyroid function remained normal. Impaired glucose tolerance occurred in four patients. Side-effects (diarrhoea, abdominal discomfort) were mild and transient. Asymptomatic gallstones occurred in three patients on 1500 micrograms/day and one patient on 600 micrograms/day after 6-12 months treatment. This dose-finding study shows that 100 micrograms three times daily SMS 201-995 is an effective therapy for most of the acromegalic patients we treated.

show abstract

Section: Discuss1 Onmentioning

confidence: 99%

Section: Discuss1 Onmentioning

confidence: 99%

Section: Discuss1 Onmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Biochemical Effects of Incremental Doses of the Long‐acting Somatostatin Analogue SMS 201‐995 in Ten Acromegalic Patients

Shi

Harris

Zhu

et al. 1990

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…They became of practical importance after the development of long-acting soma tostatin analogues -such as SMS 201-995 -designed for long-term treatment of endo crine disorders, for instance, endocrine gas tro-intestinal tumours [6][7][8], acromegaly [9] and eventually diabetes mellitus [10,11], The somatostatin analogue SMS 201-995 is an octapeptide with a plasma half-life of about 100 min after subcutaneous injection [12].…”

mentioning

confidence: 99%

Effect of the Somatostatin Analogue Sandostatin (SMS 201–995) on Gastrointestinal, Pancreatic and Biliary Function and Hormone Release in Normal Men

et al. 1987

View full text Add to dashboard Cite

The effect of the long-acting somatostatin analogue Sandostatin (SMS 201–995) on intestinal absorption and propagation (mouth-to-caecum transit time; MCTT), on pancreatic secretion and on gall bladder contraction after direct (secretin-pancreozymin test) and indirect stimulation (Lundh meal), and on meal-induced responses of seven gastrointestinal regulatory peptides has been investigated. In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 μg SMS 201–995 twice daily. Mean faecal fat excretion was increased to 19.2 g/ day and MCTT was three times longer during the SMS period. After duodenal infusion of a mixture containing D-galactose, D-xylose and triglycerides, SMS 201–995 significantly reduced the serum concentrations of D-galactose but increased serum levels of D-xylose. After 6 days of pretreatment, SMS 201–995 completely suppressed duodenal trypsin, lipase and bilirubin increases in response to endogenous stimulation by a Lundh meal. Concomitantly, cholecystokinin (CCK) release and gall bladder contraction were almost abolished. Compared with placebo, SMS 201–995 significantly diminished pancreatic amylase, trypsin and lipase output after stimulation with CCK, while the secretion of fluid and bicarbonate in response to secretin was unchanged. This inhibition of enzyme response was significantly more marked after a single injection of the analogue than after pretreatment for 7 days and did not reach the level of exocrine pancreatic insufficiency. CCK-induced gall bladder contraction was significantly inhibited by a single dose of 25 μg SMS 201–995 but not after 7 days of pretreatment with the somatostatin analogue.

show abstract

“…However, the short biologic half-life of somatostatin makes its use as therapeutic agent impractical (9). The synthesis of a new octapeptide somatostatin analogue, SMS 201-995, which has a 50 times longer half-life and shows much more GHand glucagon-suppressing activities (10, ll), is a major advance in this field, since this analogue could be used in clinical practice by subcutaneous injections, as is already being tested in acromegalic patients (12).…”

mentioning

confidence: 99%

Effect of the Long-Acting Somatostatin Analogue SMS 201-995 on the Glycaemic Control in Insulin-Treated Diabetics

Karamanos¹,

Tolis²,

Zoupas³

et al. 1986

Scandinavian Journal of Gastroenterology

Self Cite

View full text Add to dashboard Cite

show abstract

Therapy of Acromegaly with SMS 201-995: Long-Term Studies

Cited by 6 publications

References 5 publications

Clinical and Biochemical Effects of Incremental Doses of the Long‐acting Somatostatin Analogue SMS 201‐995 in Ten Acromegalic Patients

Clinical and Biochemical Effects of Incremental Doses of the Long‐acting Somatostatin Analogue SMS 201‐995 in Ten Acromegalic Patients

Effect of the Somatostatin Analogue Sandostatin (SMS 201–995) on Gastrointestinal, Pancreatic and Biliary Function and Hormone Release in Normal Men

Effect of the Long-Acting Somatostatin Analogue SMS 201-995 on the Glycaemic Control in Insulin-Treated Diabetics

Contact Info

Product

Resources

About